In vitro activity of human chorionic gonadotropin (hCG) - Doxorubicin conjugates against ovarian cancer cells

Anticancer Research

Volumn 20, Issue 5, 2000, Pages 3001-3006

  Beck, E P ^a   Vincenti, D ^a   Licht, P ^a   Berkholz, A ^a   Jager, W ^a   Lang, N ^a   Merkle, E ^a  

^a Staedtische Frauenklinik Stuttgart   (Germany)

Author keywords

Doxorubicin; HCG conjugates; Ovarian cancer; Tumor targeting

Indexed keywords

CHORIONIC GONADOTROPIN; CRYSTAL VIOLET; DOXORUBICIN; GLUTARALDEHYDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG UPTAKE; HUMAN; HUMAN CELL; MITOSIS INHIBITION; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; TARGET CELL;

ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL SURVIVAL; CHORIONIC GONADOTROPIN; DOXORUBICIN; DRUG SYNERGISM; FEMALE; HUMANS; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0033789843     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study
2. Phase II study of cis-dichlorodiammineplatinum (II) (NCS 119875) in advanced adenocarcinoma of the ovary
3. Chemotherapy in advanced ovarian cancer: An overview of randomized clinical trials
4. Carboplatin versus cisplatin
5. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
6. Options for primary chemotherapy in advanced ovarian cancer: The European perspective
7. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis
8. Continuous culture of fused cells secreting antibody of predifined specificity
9. Antibody conjugates for the treatment of cancer
10. Chemoimmunoconjugates for the treatment of cancer
11. Overview of radioimmunotherapy: A European perspective
12. Sensitivity of multidrug-resistant MCF-7 cells to a transferrin-doxorubicin conjugate
13. Transferrin conjugates of doxorubicin: Synthesis, characterization, cellular uptake, and in vitro efficacy
14. A randomized comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer
15. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group
16. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone
17. Influence of luteinizing hormone on cell growth and CA 125 secretion of primary epithelial ovarian carcinomas in vitro
18. Human chorionic gonadotropin (hCG) inhibits cisplatin-induced apoptosis in ovarian cancer cell: Possible role of up-regulation of insulin like growth factor-1 by hCG
19. Induction of ovarian tumors by endogenous gonadotropins in rats bearing intrasplenic ovarian grafts
20. Gonadotropin-releasing hormone agonist suppression of ovarian tumors in mice of the Wx/Wv genotype
21. Suppression of gonadotropins inhibits gonadal tumorigenesis in mice transgenic for the mouse inhibin alpha-subunit promoter/simian virus 40T-antigen fusion gene
22. Direct gold-silver method for hCG binding to specific tissue structures
23. Messenger ribonucleic acid expression of LH/hCG receptor gene in human ovarian carcinomas
24. Conjugates of human chorionic gonadotrophin (hCG) and cisplatin: Antiproliferative action against NIH: OVCAR 3 ovarian cancer cells in vitro
25. Coupling a preactivated daunorubicin derivative to antibody. A new approach
26. Standard kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity
27. Carboplatin plus paclitaxel as first line chemotherapy in previously untreated advanced ovarian cancer
28. The covalent binding of daunomycin and adriamycin to antibodies with retention of both drug and antibody activities
29. In vitro cytotoxicity of conjugate adriamycin with anti-sarcoma monoclonal antibody 19-24
30. Antibody-targeted liposomes to deliver doxorubicin to ovarian cancer cells
31. Killing of human tumor cells in culture with adriamycin conjugates of human transferrin
32. Doxorubicin: Monoclonal antibody conjugate for therapy of human cervical carcinoma
33. Evaluation of the potential of transferrin-adriamycin conjugates in the treatment of bladder cancer
34. Transferrin conjugates of adriamycin are cytotoxic without intercalating nuclear DNA
35. Daunorubicin conjugated to monoclonal anti CA-125 antibody selectively kills human ovarian cancer cells
36. Lutropin/choriogonadotropin down-regulates its receptor by both receptor-mediated endocytosis and a cAMP-dependent reduction in receptor mRNA
37. In vitro activity of immunoconjugates between cisplatin and an anti-CA 125 monoclonal antibody on ovarian cancer cell lines
38. Transferrin receptor growth control in normal and transformed cells